- Home
- ECOR vs HBIO Comparison
ECOR vs HBIO Comparison
Compare ECOR & HBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ECOR | HBIO |
|---|---|---|
| Founded | 2005 | 1901 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.0M | 25.7M |
| IPO Year | 2018 | 2000 |
Fundamental Metrics
Financial Performance| Metric | ECOR | HBIO |
|---|---|---|
| Price | $6.50 | $0.53 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $22.00 | $2.50 |
| AVG Volume (30 Days) | 49.2K | ★ 377.0K |
| Earning Date | 04-13-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 53.51 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $25,182,000.00 | ★ $116,176,000.00 |
| Revenue This Year | $28.92 | N/A |
| Revenue Next Year | $32.50 | $7.80 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 57.09 | N/A |
| 52 Week Low | $4.16 | $0.28 |
| 52 Week High | $13.81 | $0.95 |
Technical Indicators
Market Signals| Indicator | ECOR | HBIO |
|---|---|---|
| Relative Strength Index (RSI) | 46.83 | 40.34 |
| Support Level | $4.64 | $0.41 |
| Resistance Level | $6.61 | $0.55 |
| Average True Range (ATR) | 0.70 | 0.04 |
| MACD | -0.06 | -0.00 |
| Stochastic Oscillator | 25.73 | 33.39 |
Price Performance
Historical ComparisonAbout ECOR electroCore Inc.
electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.
About HBIO Harvard Bioscience Inc.
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, pharmaceutical and therapy discovery, bioproduction, and pre-clinical testing for drug development. Its primary focus is scientific instruments used to advance life sciences and research. With operations in North America, Europe and china it sells through a combination of direct and distribution channels to customers around the world. The product brands of the company include Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, and Panlab. The majority of its revenue comes from the United States.